NALIRIFOX (liposomal irinotecan-based chemotherapy).

Phase 2Small molecule

NALIRIFOX (liposomal irinotecan-based chemotherapy). is one of 40 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerRecruiting

Pancreatic CancerPhase 2

Recruiting

Competition

Competitive Landscape

307 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Byetta

AstraZeneca

Preclinical

1 3

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 4

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

NALIRIFOX (liposomal irinotecan-based chemotherapy).

SShandong Cancer Hospital and Institute

Phase 2

1 9

Secretin-Ferring

Ferring

Preclinical

1 10

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Pancreatic Cancer

NCT07173387

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer: A Prospective Clinical Trial

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT07173387·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NALIRIFOX (liposomal irinotecan-based chemotherapy).. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NALIRIFOX (liposomal irinotecan-based chemotherapy). compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NALIRIFOX (liposomal irinotecan-based chemotherapy).. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Cancer Hospital and Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShandong Cancer Hospital and Institute

NALIRIFOX (liposomal irinotecan-based chemotherapy).

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News